Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. - Wikidata - awgldk - TriplyDB

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

http://www.wikidata.org/entity/Q36108095

about

Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth Myeloid-derived suppressor cells: linking inflammation and cancer Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells mTOR inhibitors effects on regulatory T cells and on dendritic cells The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance MicroRNAs: Novel immunotherapeutic targets in colorectal carcinoma Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer?Overcoming Hypoxia-Mediated Tumor Progression: Combinatorial Approaches Targeting pH Regulation, Angiogenesis and Immune Dysfunction Myeloid cell signatures in tumor microenvironment predicts therapeutic response in cancer Tumour progression and metastasis Prognostic and Predictive Significance of Stromal Fibroblasts and Macrophages in Colon Cancer Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment The impact of the myeloid response to radiation therapy The Role of TLR4 in Chemotherapy-Driven Metastasis Therapeutic cancer vaccines: past, present, and future Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances Immune regulation of bone metastasis Myeloid-derived suppressor cells as therapeutic target in hematological malignancies Myeloid-derived suppressor cells in cancer: therapeutic, predictive, and prognostic implications Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials Regulation of tumor metastasis by myeloid-derived suppressor cells Oncolytic viruses as anticancer vaccines Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy Immunosuppression associated with chronic inflammation in the tumor microenvironment Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected Myeloid-derived suppressor cells as regulators of the immune system Myeloid-derived cells are key targets of tumor immunotherapy Orchestration of angiogenesis by immune cells Peripheral immune cell gene expression changes in advanced non-small cell lung cancer patients treated with first line combination chemotherapy Coordinated regulation of myeloid cells by tumours Identification of myeloid derived suppressor cells in dogs with naturally occurring cancer A PK2/Bv8/PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis Excess circulating alternatively activated myeloid (M2) cells accelerate ALS progression while inhibiting experimental autoimmune encephalomyelitis

P2860

Q21560837-7C8125FD-7342-48A6-9F31-24D83C3E805F Q24641811-D7FCF855-CFDC-44AA-87F1-0C077266348F Q24658240-E57B7242-1E81-4F92-8CC7-561B0A563087 Q26744447-AB50CD06-80AF-4D1A-9877-92C80ACEE206 Q26746986-55DE30EC-7743-42C1-86E8-2146B5C78CA5 Q26747339-5C18DA96-3CF3-4DCD-84A3-58DF6910CF71 Q26747695-A9250364-7CF6-4A31-88B9-DCED315E03F8 Q26749333-D6751C42-4BD3-49C3-BDDB-9CE659E1D40E Q26752838-CD0D61FA-E4A8-4D4C-8338-237AE43609CA Q26766468-14AAF83D-19BC-44D0-B759-D6459345525E Q26777108-EAEADA15-4D69-47E9-8B0E-A684420F462D Q26779184-850455E7-80F8-42C8-A483-9D8C00BD06B2 Q26799126-D69AA394-06C6-443F-A208-05020E11D0A8 Q26851643-0E397F93-0981-49A5-AA21-A84A5B36D10E Q26861495-676AB826-D7CD-47DB-9F80-BA5FA757AF24 Q26863283-1657BEB4-B23B-4103-A174-4A2A7AB7F62A Q26863418-062A5F26-3CA2-47FD-B98E-7B4F579C0AAF Q26863779-89AFBA5A-2CDE-47DF-BBA8-EFBFCCA75953 Q27005871-F3BA069D-59BC-4D54-B49B-507D108C1A67 Q27010234-B4CAFBDD-7052-4DF3-9235-4EA361260227 Q27014189-9484C661-4449-4CFA-815A-C646441923EE Q27014829-4650C81C-DF5D-414A-8802-50AB9CB4B7A4 Q27022125-242727FD-20EB-4F59-831C-06DB446D998D Q27025600-724C2E85-E027-40A7-A993-0AE14BE2D7F6 Q27317214-5D09F1A5-BF16-468E-B84B-6EB79E5C8B86 Q28077635-CF85F46F-4688-45E9-B1DD-F7B38A05005E Q28080262-A8745554-249E-4534-8F5B-6D13839878B4 Q28082461-AA33CAA3-5467-460E-818C-3D1D4735E800 Q28083450-AC03EFC5-F44B-4DFB-9F4A-293201B89AD4 Q28084627-E7F4F6BC-E955-4A43-B183-4C78E832E854 Q28131637-BC6205D6-3DB0-486F-A604-3050138071EE Q28388246-324CFC14-7D8C-4593-AAC1-F91223FA7C6F Q28389236-49DF351F-40CA-4602-B467-63441BEFE839 Q28394867-7AB6BFAE-1C72-40C6-8439-D1B878377BFE Q28395157-B041EB04-DFEB-4FB9-A1F9-773DDD9194AF Q28481476-540C9ED1-1F46-470F-B01A-1686071691E1 Q28485246-320AFA5C-1D36-4F65-AFA2-27E839B4E85C Q28506334-605C031C-516C-4498-BAB4-7C23BB401FF8 Q28552296-0F7B64E0-14E3-4B2D-A92E-1C05E103811B Q28743158-5E2CC6AF-931F-4312-AE2B-35E7AD12F1FE

P2860

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

http://www.wikidata.org/entity/Q36108095

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@ast

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@en

type

label

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@ast

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@en

prefLabel

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@ast

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@en

P1433

Q36108095-A672890B-04A9-40B1-8543-4AB099BFE6F1

P1476

Q36108095-6B3CB702-94BF-4EF7-80B7-E5E6F47FC39C

P2093

Q36108095-42F3BD3E-B7F6-4C50-836A-26C759A191D6

Q36108095-557401C6-3307-40C8-89F2-167FB1A13206

Q36108095-74314212-00E2-4A48-B729-B9044E707657

Q36108095-BFDBBF1E-94AA-4250-920D-7C32A05337F2

Q36108095-C2425321-5F15-4EF9-915F-B689FDA1BD33

Q36108095-D9EB5604-ADDA-4B31-BF1A-CD5522490E17

P2860

Q36108095-1EABE30D-CCCC-44EF-9FC6-E31054136F56

Q36108095-2458AAA1-F067-4D52-A1E6-02A99CE80571

Q36108095-3CCF9B31-F70E-421E-B98E-7499C9BD24CF

Q36108095-3EA9BE0D-3A50-424C-AC3F-7A8E3318C056

Q36108095-3EF571FB-1D0F-400E-9C42-72A7AFE3F455

Q36108095-5615C5DB-D3CF-4F60-8FB7-755063D2A797

Q36108095-64264A26-E21D-416F-99D8-6E6C1061ADEF

Q36108095-6A0D3F56-2541-4259-B829-A99F4B15BAE7

Q36108095-83833409-3669-4D5E-8C6B-82480404D737

Q36108095-84AD6C05-3EF6-44EB-BE5D-933898ED57F6

P2888

Q36108095-8C8AE784-ED10-4A86-ACCD-600FA04D6E17

P304

Q36108095-AE4C5CDF-CA78-44A5-B464-2A4EAB157AA0

P31

Q36108095-424A7351-0492-488A-9A1C-8FE88F71742E

P356

Q36108095-2C2D1305-EF19-4066-98D2-C14B83355580

P433

Q36108095-F272CCDF-87CC-49E7-886A-6A6B06181834

P478

Q36108095-D6580CBE-67B2-4B60-BA0B-178AB8C0706A

P577

Q36108095-420805E5-6F05-45D6-B64C-4EDFBD3E12F8

P5875

Q36108095-2625223F-0EC2-4040-A453-CFB10A598751

P698

Q36108095-325A3616-D7B3-47A0-8E89-CA4B824897DC

P921

Q36108095-64FCAC6B-46E1-4BC7-A05A-179FDB8B5EE9

P932

Q36108095-10667609-5B5A-4A8C-9BE8-11A1925B9202

P356

S00262-008-0523-4

P1433

Cancer Immunology, Immunotherapy

P1476

Increased circulating myeloid- ...... cyclophosphamide chemotherapy.

@en

P2093

Alberto J Montero

http://www.w3.org/2001/XMLSchema#string

C Marcela Diaz-Montero

http://www.w3.org/2001/XMLSchema#string

David J Cole

http://www.w3.org/2001/XMLSchema#string

Elizabeth Garrett-Mayer

http://www.w3.org/2001/XMLSchema#string

Michael I Nishimura

http://www.w3.org/2001/XMLSchema#string

Mohamed Labib Salem

http://www.w3.org/2001/XMLSchema#string

P2860

Nitric oxide-producing CD11b(+)Ly-6G(Gr-1)(+)CD31(ER-MP12)(+) cells in the spleen of cyclophosphamide-treated mice: implications for T-cell responses in immunosuppressed mice

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species.

Tregs and rethinking cancer immunotherapy.

Immature myeloid cells and cancer-associated immune suppression.

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.

Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells

Cancer vaccines: moving beyond current paradigms.

Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.

P2888

s00262-008-0523-4

P304

49-59

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00262-008-0523-4

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P577

2008-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5406779

http://www.w3.org/2001/XMLSchema#string

P698

18446337

http://www.w3.org/2001/XMLSchema#string

P921

P932

3401888

http://www.w3.org/2001/XMLSchema#string